Hyperkalemia Antibiotic treatment Adverse drug reaction
Conditions
Interventions
We will compare several parameters in two groups. Our experimental/intervention group will consist of patients admitted to the Canisius Wilhelmina hospital who receive at least 1920mg of intravenous c
Sponsors
Canisius Wilhelmina Hospital, department of Clinical Pharmacy, Nijmegen, the Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: - Admission date to the Canisius Wilhelmina hospital in the period of January 1st 2013 until December 31st 2015 - Receiving at least 1920mg intravenous co-trimoxazole per 24h for at least 48h or at least 2g intravenous ceftriaxone per 24h for at least 48h
Exclusion criteria
Exclusion criteria: - Age under 18 years at the day of start of antibiotic treatment - Admission to the intensive care unit during the antibiotic treatment period - Severe kidney disease (defined as at least one measurement of 7,55 during the antibiotic treatment period) - Simultaneous administration of both co-trimoxazole and ceftriaxone during the antibiotic treatment period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will compare the surges in serum potassium levels of both groups. We will compare these surges in serum potassium by measuring serum potassium before and after the start of antibiotic treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will measure several secondary outcomes, including serum creatinin (before and after the start of antibiotic treatment), the incidence of hyperkalemia, co-factors that influence serum potassium, the amount of serum potassium measurements (before and after the initiation of antibiotic therapy, as a variable to measure medication safety), hyperkalemia-associated complications such as mortality and a possible dose-response effect on serum potassium in the co-trimoxazole group. | — |
Outcome results
None listed